Handok (002390.KS) Stock Price

Handok Price

KOSPI·CLOSED
8,610.00
​
Market closed

Over the last 19 years Handok grew revenue by 4.3% annually, reaching 535.14 B KRW. Earnings per share have declined at 4.1% per year over the last 16 years. For Handok, the net margin of -0.4% is down versus 0.6% a few years ago. At today's price the dividend yield works out to roughly 2.32%.

Handok stock price

Access this data via the Eulerpool API

Handok business model & stock analysis

Handok, Inc. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Seoul, Seoul. The firm's products include Amaryl for diabetes; Tritace for hypertension, myocardial infarction, heart failure and other cardiovascular diseases; Teveten and Triapin for essential hypertension; Munobal for hypertension and stenocardia; Ketas for disturbance of cerebral circulation; Lasix for hypertension and edema, and remedies for skin and others. The company also provides over-the-counter (OTC) pharmaceuticals, healthcare products, as well as medical devices, diagnostic reagents and vaccines. In addition, the Company is involved in the real estates rental business. On July 26, 2013, it changed its name to HANDOK Inc. from Handok Pharmaceuticals Co., LTD.

Frequently asked questions about Handok

5 analysts currently rate the Handok stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Handok to generate revenue of 422.80 B KRW and earnings per share of -248.00 KRW.

Converted at the current exchange rate, the Handok share trades at 5.73 EUR (8,610.00 KRW).

The Handok share (002390.KS) is listed on 1 stock exchanges, including: KOSPI (Seoul) (002390.KS).

The expected revenue of Handok is 422.80 B KRW. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Handok is -3.41 B KRW. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Handok is currently -34.72. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Handok stock.

The price-to-sales ratio (P/S) of Handok is currently 0.28. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Handok stock.

The Eulerpool Quality Score for Handok is 0/10.

The ISIN of Handok is KR7002390003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Handok is 002390.KS. The ticker symbol is used to trade Handok shares on the stock exchange.

Fair ValueTerminal
7,662.90 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website handok.co.kr
Country
South Korea
Currency
KRW
Initial public offering
Jun 30, 1976
ISIN
KR7002390003
Cusip
Y3R01Q117
Market capitalization
118.50 B KRWLarge Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-34.72
P/Ee 2027
13.65
P/Ee 2028
8.49
P/Ee 2029
13.50
P/Ee 2030
7.56
P/S
P/Se
0.28
EV/EBIT
52.85
P/B Ratio
0.43
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-0.60 %
Dividend
Dividend yield
2.32 %
Est. Dividend Yield
2.32 %
Payout Ratio
-127.85 %
Dividend growth Ø5Y
-12.94 %
Dividend payments per year
1
Dividend paid since
1 year
Dividend not reduced since
1 year
Dividend increased since
1 year
Dividend withholding tax
22.00 %
Last updated Oct 9, 2026, 11:33 PM

Handok Peer Group

Handok Ticker

KOSPI · 002390.KS

Handok FIGI

002390:KS · BBG000BDHPQ6002390:KP · BBG000BDHQN7

All fundamentals and in-depth analysis of Handok

Our stock analysis for Handok stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Handok. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.